| 41 |
|
AML: clustering genes to predict outcome/
|
Ness, S. A
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 42 |
|
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases/
|
Schoch, C
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 43 |
|
Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases/
|
Wolf, K
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 44 |
|
Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor/
|
Michaux, G
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 45 |
|
Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolism/
|
James, M. J
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 46 |
|
Angiogenic effects of prostaglandin E~2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells/
|
Salcedo, R
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 47 |
|
Angiopoietin expression in multiple myeloma/
|
Bellamy, W. T
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 48 |
|
Announcements ///
|
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 49 |
|
Announcements ///
|
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 50 |
|
Announcements ///
|
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 51 |
|
Announcements ///
|
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 52 |
|
Another advance for globin gene therapy/
|
Bodine, D. M
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 53 |
|
Another way for sPLA~2 to meet with cells/
|
Murakami, M
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 54 |
|
Antiapoptotic effect of coagulation factor VIIa/
|
Sorensen, B. B
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 55 |
|
Anti-beta2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome/
|
Galli, M
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 56 |
|
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of ^9^0Y-DOTA-peptide-Lym-1 in lymphoma xenografts/
|
Tuscano, J. M
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 57 |
|
Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist/
|
Coopamah, M. D
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 58 |
|
Antigen-primed CD8^+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing/
|
Komatsu, M
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 59 |
|
Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study/
|
Gris, J.-C
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 60 |
|
Anti-rIL-2 receptor antibodies and marrow aplasia/
|
Slavin, S
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|